SCHEMBL5135791

SCHEMBL5135791

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1c(OC)cc(OC)cc1OC)CC1CCCCC1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.38
PDE5A O76074 1/20 0.36
CRHR1 P34998 7/20 0.35
HDAC1 Q13547 1/20 0.35
TSHR P16473 2/20 0.34
TP53 P04637 1/20 0.34
GAA P10253 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
CYP3A4 P08684 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
ADORA2B P29275 1/20 0.34
ADORA1 P30542 1/20 0.34
CASR P41180 1/20 0.33
BCHE P06276 3/20 0.33
AKT1 P31749 1/20 0.33
AKT2 P31751 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135638 0.90 C5AR1 (0.39) C5AR1CRHR1HDAC1TSHRGAA
SCHEMBL648304 0.90 C5AR1 (0.41) C5AR1CRHR1HDAC1TSHRKDM4E
SCHEMBL5135852 0.89 C5AR1 (0.40) C5AR1CRHR1HDAC1TP53GAA
SCHEMBL5137556 0.87 C5AR1 (0.40) C5AR1HDAC1TSHRTP53KDM4E
SCHEMBL5137557 0.87 C5AR1 (0.42) C5AR1TSHRTP53GAASMN1; SMN2
SCHEMBL648140 0.87 C5AR1 (0.44) C5AR1TP53GAASMN1; SMN2ALDH1A1
SCHEMBL5137356 0.87 MEN1 (0.45) C5AR1SMN1; SMN2ALDH1A1CYP3A4ADORA2B
SCHEMBL5136939 0.86 CRHR1 (0.42) C5AR1PDE5ACRHR1HDAC1TSHR
SCHEMBL651501 0.86 C5AR1 (0.44) C5AR1CRHR1HDAC1TSHRKDM4E
SCHEMBL5137023 0.85 C5AR1 (0.42) C5AR1PDE5ACRHR1TSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed